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and assumptions were based on the NICE/External Assessment Centre report and 
published literature when possible. Results: Adoption of Sherlock 3CG® TCS was 
predicted to be more or less cost neutral per patient when compared with “blind” 
bedside in both the U.K. (£9.37) and the U.S. ($18.73). Further, Sherlock 3CG® TCS 
was predicted to be cost-saving per patient compared with fluoroscopy in the U.K. 
(-£106.12) or compared with a TLS in the U.S. (-$18.43). These results were robust 
to the majority of sensitivity analyses. ConClusions: This study predicts that 
Sherlock 3CG® TCS is an economically favorable strategy from both U.K. and U.S. 
perspectives and can provide additional patient and healthcare worker benefits. 
Additional analyses in other regions may help to further substantiate these results.
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objeCtives: Although several hemostats are available, drawbacks include limita-
tions with efficacy and ease-of-use. Despite their use, uncontrolled bleeding still 
remains common and is associated with important clinical and economic burden. 
A study was conducted to estimate the economic impact of a novel fibrin sealant 
matrix (EVARREST®) versus standard of care (SoC) in problematic severe soft tissue 
surgical bleeding in Germany. Methods: An economic model quantified 30-day 
cost impact of EVARREST® from a German hospital perspective. Severe soft tis-
sue bleeding trial resources included quantity of initial treatment, re-treatment, 
surgery time, transfusion risk, amount transfused, and hospitalization (including 
ICU and ward stay). SoC was composed of Surgicel® (88%) and conventional meth-
ods (e.g., manual compression). The surgical analysis included resources clinically 
related to the significant hemostasis benefit of EVARREST®vs. SoC (i.e., initial and 
re-treatment, operating time, transfusion). A hospital analysis included all resources 
collected. Published data on German costs were applied to resource use. A sub-
group analysis was conducted for patients meeting coagulopathic criteria based 
on abnormal values for at least one of the trial coagulation parameters collected. 
Value-added tax (19%) was added to product costs. Results: The surgical base-case 
analysis predicted that EVARREST® cost was offset by averted resource use with per 
patient cost impact of € 1,893 vs. SoC. The hospital analysis predicts further resource 
reduction with EVARREST® leading to cost impact of € 608 per patient. In coagulo-
pathic patients, the results dramatically improved, with the surgical and hospital 
analysis both showing cost-savings of € 542 and € 3,275 with EVARREST®vs. SoC 
respectively. ConClusions: In problematic bleeding situations, EVARREST® may 
result in important cost savings for hospitals, in addition to meeting an important 
unmet need. This analysis suggests results may depend on surgical bleeding type, 
with increased benefit seen in challenging (i.e., coagulopathic) bleeding patients. 
Further study is needed to confirm findings.
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objeCtives: Although several hemostats are available, drawbacks include limita-
tions with efficacy and ease-of-use. Despite their use, uncontrolled bleeding still 
remains common and is associated with important clinical and economic burden. 
A study was conducted to estimate the economic impact of a novel fibrin sealant 
matrix (EVARREST®) versus standard of care (SoC) in problematic severe soft tissue 
surgical bleeding in Italy. Methods: An economic model quantified 30-day cost 
impact of EVARREST® from an Italian hospital perspective. Severe soft tissue bleed-
ing trial resources included quantity of initial treatment, re-treatment, surgery time, 
transfusion risk, amount transfused, and hospitalization (including ICU and ward 
stay). SoC was composed of Surgicel® (88%) and conventional methods (e.g., manual 
compression). The surgical analysis included resources clinically related to the sig-
nificant hemostasis benefit of EVARREST®vs. SoC (i.e., initial and re-treatment, 
operating time, transfusion). A hospital analysis included all resources collected. 
Published data on Italian costs were applied to resource use. A subgroup analysis 
was conducted for patients meeting coagulopathic criteria based on abnormal val-
ues for at least one of the trial coagulation parameters collected. Results: The 
surgical base-case analysis predicted that EVARREST® cost was offset by averted 
resource use with per patient cost impact of € 1,016 vs. SoC. The hospital analysis 
predicts further resource reduction with EVARREST® leading to cost-savings of € 708 
per patient. In coagulopathic patients, the results dramatically improved, with the 
surgical and hospital analysis both showing cost-savings of € 2,366 and € 6,128, with 
EVARREST®vs. SoC respectively. ConClusions: In problematic bleeding situations, 
EVARREST® may result in important cost savings for hospitals, in addition to meet-
ing an important unmet need. This analysis suggests results may depend on surgi-
cal bleeding type, with increased benefit seen in challenging (i.e., coagulopathic) 
bleeding patients. Further study is needed to confirm findings.
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objeCtives: economic analysis of telemedical technologies application for regular 
medical examination among the adult population living far from hospitals in the 
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objeCtives: Presently, there is a disparity between the purchasing power of vari-
ous hospital institutions within Germany. Large institutions, those within hospital 
networks, and those with group purchasing organization (GPO) memberships can 
leverage their influence to secure favorable prices for medical devices and consuma-
bles. Other institutions, however, are not able to leverage the same purchasing power, 
resulting in higher prices and financial inefficiencies. The objective of this work was 
to measure the financial impact to a broad spectrum of hospitals using real-world 
German hospital purchasing and consumption data. Methods: GfK Hospital Panel, a 
proprietary database for German hospital medical devices and consumables purchas-
ing and consumption was evaluated. Wound care purchasing data was evaluated to 
see similarities and differences in purchasing volume, acquisition cost, and product 
utilization. Products used to promote infection control and healing in post-surgical 
sites were prioritized. Results: The hospital purchasing and consumption data 
identified how specific products were used within and across hospitals. Differences 
in consumption by specialty department/units show how purchasing decisions are 
being concentrated in different settings. Hospitals with greater buying power and 
those with access to group purchasing organizations paid less per unit price than 
other hospitals, however the mix of products used varied by setting. Advanced wound 
care products had the greatest variability in usage among hospitals within the sam-
ple. ConClusions: Databases that provide detailed hospital purchasing data provide 
greater transparency to both hospitals and innovators on purchasing, pricing, and 
utilization trends. Smaller hospitals and those independently negotiating purchasing 
contracts can leverage this information to understand practice in other hospital set-
tings as they make decisions for their own. These data are likely to have a significant 
impact in rationalizing expenditures across the German Healthcare System, providing 
transparency to help hospitals make better purchasing decisions.
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objeCtives: Intraoperative watertight dural closure is critical as CSF leakage can 
lead to an increased risk of costly clinical consequences (e.g., wound infection, men-
ingitis). Although there are several fibrin sealants available, not all are indicated 
for sealing dura mater. An economic analysis compared a fibrin sealant (EVICEL® 
Solutions for Sealant) with standard of care (SoC) for sutured dural closure in cranial 
surgery in the United Kingdom (UK). Methods: The economic analysis quantified 
the 30-day cost impact of EVICEL® from a U.K. hospital perspective based on a surgical 
approach using clinical trial data. SoC was composed of sutures in addition to rescue 
therapy for the majority of the population. Trial-reported resources used included 
the quantity of initial treatment, adjunctive and rescue therapy product utilization, 
operating room (OR) time, hospitalization duration, and risk of dural-related adverse 
events. Only SoC treatment successes were allowed to receive additional adjunctive 
therapies to ensure durability of closure; however, treatment failures in both Evicel® 
and SoC could receive rescue therapies. Adjunctive therapies consisted of sutures, 
collagen, and haemostats (not fibrin sealants); where as rescue therapies consisted 
of various glues, haemostats and autologous dural patches. Published data on U.K. 
costs were applied to resource use and several one-way sensitivity analyses were 
conducted. Results: The analysis estimated that resource savings with EVICEL® 
completely offset its acquisition cost and resulted in cost savings of £207 per patient 
(sensitivity range: -£727.02 to £313.40) compared with SoC. Results remained robust 
to the majority of sensitivity analyses; however were most sensitive to assumptions 
regarding OR time and hospitalization duration. ConClusions: The use of EVICEL® 
for suture line dural closure may result in important cost savings for hospitals, partly 
driven by the reduced need for other adjunctive and rescue therapies. Further studies 
in larger populations may help to substantiate findings.
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objeCtives: The Sherlock 3CG® Tip Confirmation System (TCS) is designed to con-
firm the correct tip placement of a peripherally inserted central catheter (PICC) by 
using magnetic real-time tracking and electrocardiographic catheter tip confirma-
tion. The National Institute for Health and Care Excellence (NICE) recommended 
the adoption of Sherlock 3CG® TCS based on modelled health economic benefits 
in the United Kingdom (U.K.). The objective of this study was to develop a United 
States (U.S.) model for Sherlock 3CG® TCS and compare these results to the U.K. 
analyses. Methods: Sherlock 3CG® TCS was compared with “blind” beside PICC 
placement, as well as region-specific PICC placement methods (i.e., fluoroscopy in 
the U.K. and tip location system (TLS) in the U.S.). Clinical and economic outcomes 
were assessed per patient over the duration of a successful PICC insertion procedure. 
All eligible patients with an identifiable P-wave in their ECG rhythm were assumed 
to switch to Sherlock 3CG® TCS and did not require confirmatory chest x-rays. PICC 
placement success rates, as well as region-specific costs for capital, maintenance, 
nurse training, consumable materials, and chest x-rays were included. Parameters 
